As of Dec 20, 2024, the Adma Biologics stock's PE ratio is 60.0. This takes into account the latest EPS of $0.29 and stock price of $17.4.
Year | PE ratio | Change |
---|---|---|
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | N/A | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
ADMA Adma Biologics Inc | 60 | $4.11B |
NVAX Novavax Inc | N/A | $1.39B |
RGEN Repligen Corp | N/A | $8.09B |
CVM Cel Sci Corp | N/A | $44.88M |
ADMA's price to earnings ratio is 60 as of Dec 20, 2024.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Dec 20, 2024), Adma Biologics's share price is $17.4. The company's earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $0.29. Therefore, Adma Biologics's PE ratio for today is 60. PE RATIO(60) = STOCK PRICE($17.4) / TTM EPS($0.29)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.